INNOVATE Corp VATE 深 滬
已收盤 02-06 16:00:00 美东时间
5.31
-0.100
-1.85%
華盛通- 最 高5.58
- 今 開5.48
- 成交量 1.38万股
- 最 低 5.20
- 昨 收 5.41
- 總市值 7250.84万
- 52周最高 13.19
- 市盈率 靜 --
- 換手率 0.10%
- 52周最低 4.05
- 委 比 0.00%
- 總股本 1365.51万
- 歷史最高 170.1074
- 量 比 0.55
- 振 幅 7.02%
- 歷史最低 4.05
- 每 手 1
- 風險率 1.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多INNOVATE Corp Subsidiary DBM Global Declares Cash Dividend
An update from INNOVATE Corp ( ($VATE) ) is now available. On February 2, 2026,...
02-02 21:59
INNOVATE’s Portfolio Company DBM Global to Pay Cash Dividend
<p>INNOVATE Corp. announced that its subsidiary, DBM Global Inc. (DBMG), will pay a cash dividend of approximately $5 million ($1.30 per share) on February 24, 2026, to stockholders of record as of February 9, 2026. INNOVATE, as DBMG’s largest stockholder, expects to receive approximately $4.6 million of the total payout. The dividend is not available to INNOVATE’s individual stockholders. DBMG provides integrated steel construction services and ...
02-02 13:30
Innovate Q3 EPS $(0.71) Up From $(1.18) YoY, Sales $347.100M Up From $242.200M YoY
Innovate (NYSE:VATE) reported quarterly losses of $(0.71) per share. This is a 39.83 percent increase over losses of $(1.18) per share from the same period last year. The company reported $347.100 million in sales this
2025-11-13 05:04
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
2025-11-12 19:11
INNOVATE Announces MediBeacon's Transdermal GFR System Receives NMPA Approval In China, Plans Year-End Launch
•MediBeacon®Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function•The TGFR will be available for sale in China
2025-10-21 21:22
MediBeacon receives regulatory approval to sell the Transdermal GFR System in China
MediBeacon's Transdermal GFR System (TGFR), featuring Lumitrace injection, has received approval in China for assessing kidney function in patients with normal or impaired renal function. The system will be available for sale in China before the end of the year, offering a non-invasive, real-time alternative to traditional kidney function tests. TGFR measures the clearance of a fluorescent agent transdermally, providing accurate and immediate res...
2025-10-21 12:05
Innovate declares $2.28 dividend
Innovate (NYSE:VATE) declares $2.28/share dividend. Payable Nov. 10; for shareholders of record Oct. 27; ex-div Oct. 27. See VATE Dividend Scorecard, Yield Chart, & Dividend Growth. More on Innovate ...
2025-10-17 09:14
INNOVATE Corp Subsidiary Announces $8.8M Dividend
INNOVATE Corp ( ($VATE) ) just unveiled an announcement. On October 16, 2025, I...
2025-10-17 05:48
INNOVATE’s Portfolio Company DBM Global to Pay Cash Dividend
INNOVATE Corp. subsidiary DBM Global Inc. will pay a $8.8 million cash dividend ($2.28 per share) on November 10, 2025, to stockholders of record as of October 27, 2025. INNOVATE, as DBMG's largest shareholder, expects to receive approximately $8 million of the total payout. Individual INNOVATE stockholders are not eligible to receive the dividend.
2025-10-16 20:15
INNOVATE’s Portfolio Company, R2, has Explosive Growth and Global Reach with Glacial® Skin Continuing to Redefine Aesthetic Innovation
INNOVATE Corp. subsidiary R2 Technologies reported a 88% revenue increase in Q2 2025, driven by Glacial Skin technology's strong performance in global aesthetics. Global system sales rose 125%, with significant demand growth outside North America, particularly in Europe, South America, and Asia. Patient treatments increased 115%, and social media engagement surged 823% compared to industry benchmarks. Glacial Skin's ability to deliver visible res...
2025-09-09 12:39
